Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | DDO | Q99489 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204439 | 0.87 | NR4A2 (0.48) | FLT3PDGFRBKITNR4A2KIF11 | |
| SCHEMBL701020 | 0.84 | KDM4E (0.57) | FLT3PDGFRBKITDAODDO | |
| SCHEMBL915460 | 0.84 | HRH4 (0.55) | FLT3NR4A2KIF11CYP1A2GLA | |
| SCHEMBL30310659 | 0.84 | HRH4 (0.55) | FLT3NR4A2KIF11CYP1A2GLA | |
| SCHEMBL8655451 | 0.83 | HRH4 (0.56) | FLT3NR4A2KIF11CYP1A2GLA | |
| SCHEMBL2323348 | 0.83 | FLT3 (0.59) | FLT3DAODDONR4A2KIF11 | |
| SCHEMBL2205092 | 0.83 | HRH4 (0.56) | FLT3NR4A2KIF11CYP1A2GLA | |
| SCHEMBL217459 | 0.83 | FLT3 (0.66) | FLT3GLAGAAULK1KDM4E | |
| SCHEMBL5568273 | 0.83 | FLT3 (0.59) | FLT3DAONR4A2KIF11CYP1A2 | |
| SCHEMBL29425071 | 0.81 | FLT3 (0.58) | FLT3PDGFRBKITDAODDO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689639-B | Spirolactams as ROCK inhibitors | 百时美施贵宝公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3481817-B1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3481817-B1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-2435407-B1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-12-25 | — | — | EP | disclosed |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3481817-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2019-05-15 | — | — | EP | disclosed |
| US-6245761-B1 | NERVOUS SYSTEM, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2001-06-12 | — | — | US | disclosed |
| CN-1173867-A | Indolyl neuropeptide Y receptor antagonists | LILLY CO ELI (US) | 1998-02-18 | — | — | CN | disclosed |
| EP-0789688-A4 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0789688-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5563142-A | INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | THE UPJOHN COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0507861-B1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | UPJOHN CO (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5489593-A | Anti-aids piperazines | THE UPJOHN COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0507861-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS. | UPJOHN CO (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1991009849-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | FLT3 3746/4885PDGFRB 661/4885KIT 4294/4885 |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | FLT3 3746/4885PDGFRB 661/4885KIT 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.